From: Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis
Continuous variables | ICS exposed | ICS un-exposed | p value# |
---|---|---|---|
(n = 3243) | (n = 1062) | ||
Mean age (years) | 65.5 | 67.2 | < 0.0001 |
Mean BMI (kg/m2) | 26.3 | 26.6 | 0.1772 |
Smoking (pack years) | 34.7 | 39.0 | < 0.0001 |
Social deprivation (Scottish index of multiple deprivation; 1 = most deprived, 5 = most affluent) | 2.31 | 2.29 | 0.5972 |
Dyspnoea score (1 = least breathless, 5 = most breathless) | 2.57 | 2.19 | < 0.0001 |
Gender (female) | 51.9% | 49.5% | 0.1693 |
Primary CV prevention (hypertension, dyslipidaemia) | 73.4% | 79.0% | 0.0003 |
Secondary CV prevention (myocardial infarction, heart failure, stroke, PVD) | 11.3% | 15.6% | 0.0002 |
Renal diseases history | 2.9% | 2.5% | 0.4692 |
Diabetes history | 8.0% | 9.8% | 0.0711 |
Pneumonia history | 5.4% | 3.8% | 0.0375 |
Fracture history | 5.7% | 5.8% | 0.8413 |
Cataract history | 10.3% | 10.9% | 0.5840 |
Oral steroids prescription history | 58.9% | 30.0% | < 0.0001 |
Rectal steroids prescription history | 11.8% | 10.4% | 0.1971 |
Topical steroids prescription history | 61.1% | 59.8% | 0.4540 |
FEV1 baseline (Litres) | 1.63 (0.65) | 1.82 (0.63) | < 0.0001 |
Percent predicted FEV1* | 74.9 (23.3) | 85.0 (20.8) | < 0.0001 |
FEV1 /FVC ratio | 55.1 (10.9) | 59.8 (8.6) | < 0.0001 |